IRIS
JAFFRAIN, MARIE LISE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.130
AS - Asia 2.790
EU - Europa 2.789
SA - Sud America 277
AF - Africa 42
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 11.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.066
SG - Singapore 1.133
IE - Irlanda 662
CN - Cina 602
RU - Federazione Russa 538
IT - Italia 336
TR - Turchia 320
SE - Svezia 304
VN - Vietnam 294
HK - Hong Kong 271
DE - Germania 251
BR - Brasile 230
GB - Regno Unito 197
UA - Ucraina 176
FR - Francia 128
FI - Finlandia 102
CA - Canada 41
IN - India 26
JP - Giappone 26
BE - Belgio 22
BD - Bangladesh 20
MX - Messico 19
ES - Italia 17
CZ - Repubblica Ceca 14
IQ - Iraq 14
NL - Olanda 14
AR - Argentina 12
VE - Venezuela 12
AU - Australia 10
DZ - Algeria 9
ID - Indonesia 9
KR - Corea 9
PK - Pakistan 8
SA - Arabia Saudita 8
ZA - Sudafrica 8
EU - Europa 7
KZ - Kazakistan 7
MA - Marocco 7
EC - Ecuador 6
IL - Israele 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
PL - Polonia 5
PY - Paraguay 5
UY - Uruguay 5
CO - Colombia 4
KE - Kenya 4
LT - Lituania 4
AL - Albania 3
JO - Giordania 3
LB - Libano 3
MY - Malesia 3
NP - Nepal 3
UZ - Uzbekistan 3
BH - Bahrain 2
KH - Cambogia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
SC - Seychelles 2
AO - Angola 1
BF - Burkina Faso 1
CL - Cile 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EG - Egitto 1
GE - Georgia 1
GN - Guinea 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 11.048
Salva come PNG Salva come JPEG
Città #
Jacksonville 700
Chandler 682
Singapore 681
Dublin 662
San Jose 507
Dallas 381
Boardman 267
Hong Kong 267
Ashburn 258
Santa Clara 252
Council Bluffs 219
The Dalles 159
Izmir 148
Nanjing 124
San Mateo 124
New York 122
L’Aquila 114
Moscow 109
Wilmington 102
Lawrence 98
Princeton 98
Ho Chi Minh City 83
Ann Arbor 80
Lauterbourg 72
Hanoi 60
Beijing 59
Dong Ket 48
Milan 45
Des Moines 40
Nanchang 39
Hefei 38
Woodbridge 34
Dearborn 33
Los Angeles 31
Shenyang 30
L'aquila 29
Munich 29
Verona 28
Hebei 27
Mountain View 25
Seattle 25
Jiaxing 24
São Paulo 24
Tokyo 24
Kunming 23
San Francisco 23
Tianjin 22
Brussels 20
Frankfurt am Main 20
Rome 20
Columbus 18
Helsinki 18
Guangzhou 17
Toronto 17
Brooklyn 16
Orem 16
Shanghai 14
Changsha 13
Jinan 13
Brno 10
Mexico City 10
Ningbo 10
Montreal 9
Norwalk 9
Falkenstein 8
Falls Church 8
Haiphong 8
London 8
Pune 8
Zhengzhou 8
Atlanta 7
Biên Hòa 7
Caracas 7
Da Nang 7
Philadelphia 7
Rio de Janeiro 7
Stockholm 7
Baghdad 6
Changchun 6
Ninh Bình 6
Bremen 5
Montevideo 5
Mumbai 5
Nuremberg 5
Padova 5
Paris 5
Pescara 5
Taizhou 5
Amsterdam 4
Capistrello 4
Charlotte 4
Chengdu 4
Curitiba 4
Fremont 4
Houston 4
Jakarta 4
Johannesburg 4
Manchester 4
Melbourne 4
Phoenix 4
Totale 7.522
Salva come PNG Salva come JPEG
Nome #
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. 187
18F-DOPA PET/CT Physiological Distribution and Pitfalls: Experience in 215 Patients 173
L'acromégalie familiale: A propos d'une observation, revue de la littérature 157
X-linked acrogigantism syndrome: Clinical profile and therapeutic responses 153
The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein (AIP) gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect? 150
Le forme familiari di adenoma ipofisario 142
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 135
15 year-old boy with ocular palsy and headache. Invasive macroprolactinoma 133
Contenuto dei grassi nella dieta e rischio di insorgenza di carcinoma della mammella. 131
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 126
How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020 126
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. 124
Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells 124
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly 124
Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pitutuitary adenomas: pathological and clinical implications 123
Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors 122
Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. 119
Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic features 116
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC 116
Hypophysitis and Granulomatous Pituitary Lesions in Systemic Diseases 116
A Study of Alternative TrkA Splicing Identifies TrkAIII as a Novel Potentially Targetable Participant in PitNET Progression 116
HMGA1-pseudogene expression is induced in human pituitary tumors 115
Hypophysitis 115
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families 113
Aggressive prolactinoma in a child related to germline mutation in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene. 113
New insights in the pathogenesis of pituitary tumours 113
Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas 112
From resistant to aggressive and malignant prolactinomas: a translational approach 112
Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly 110
Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients 110
Clinical characterization of familial isolated pituitary adenomas 109
Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature 109
Hyperplasia-adenoma sequence in pituitary tumorigenesis related to Aryl hydrocarbon receptor Interacting Protein gene mutation. 109
Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells 109
Macroprolactinomas as a cause of delayed puberty: a report of two cases and effects of medical therapy 108
A critical re-appraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas 108
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. 108
Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. 108
Salivary gland tissues and derived primary and metastatic neoplasms: unusual pitfalls in the work-up of sellar lesions. A systematic review 108
Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art 107
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions 107
Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients 106
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy inpatients with prolactin-secreting pituitary adenomas 106
Effects of gonadal steroids on the growth of human pituitary adenomas in vitro 105
Comparison of six-months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study 105
Clinical and genetic features of familial pituitary adenomas 105
Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrine follow-up results 104
Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study 104
The genetics of pituitary adenomas 104
Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring 104
Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors 104
Relationship between blood pressure and glucose tolerance in acromegaly 103
Il ruolo dell'endocrinologo nel trattamento delle lesioni della regione sellare 102
Expression of Epidermal Growth Factor in neoplastic pituitary cells: evidence for a role in corticotrophinoma cells 101
Cardiac effects of SR-Lanreotide, a slow-release somatostatin analog, in acromegalic patients 101
Familial pituitary adenomas. 101
Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas 101
Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. 100
Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics 99
Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications 99
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 99
Influence of radiotherapy on long-term follow-up of clinically non-secreting pituitary adenomas 98
The prevalence of silent acromegaly in prolactinomas is very low 98
Infusione sequenziale di GHRH 1-29NH2, LHRH e TRH per la valutazione della riserva ipofisaria: confronto con il Politest. 97
De la génétique des adénomes hypophysaires 97
Prognostic Factors: Molecular Pathway – Tumour Suppressor Gene (MEN1) 97
A multivariable prediction model for pegvisomant dosing: Monotherapy and in combination with long-acting somatostatin analogues 97
Familial pituitary adenomas: from clinical practice to basic research 95
A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal 95
Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients 94
Two-year follow-up of acromegalic patients treated with slow release Lanreotide (30 mg) 90
Effect of 17β-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas. Correlation with specific cellular receptors 90
Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly 90
Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1 89
Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study 88
HPLC determination of urinary catecholamines as a screening test for pheochromocytoma in a patient with medullary carcinoma of the thyroid. 88
Evaluation of the adequacy of Levothyroxine replacement therapy in patients with central hypothyroidism 88
Pituitary adenomas in young patients: when should we consider a genetic predisposition? 88
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 88
Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution 88
Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update 88
The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas 86
Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience 85
Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene 84
Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. 84
Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification 84
Cellular receptors for sex steroids in human pituitary adenomas 83
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion 80
Surgical treatment of pituitary tumours in the elderly: clinical outcome and long-term follow-up 80
Epidermal growth factor (EGF)- binding sites in human pituitary adenomas 80
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. 80
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. 80
Visual improvement during octreotide therapy in a case of episellar meningioma 80
Long-term follow-up results of postoperative radiation therapy for Cushing's disease 79
Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure ? An audit of surgical results on a large series and a review of the literature 79
The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas 79
Fenofibrate has differential effects on cell proliferation and GH secretion in GH3 cells 79
Giant prolactinomas presenting as skull base tumors 78
Mir-23b and miR-130b expression is downregulated in pituitary adenomas 77
Differential expression of neurogenins and NeuroD1 in human pituitary tumours 74
Totale 10.443
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202188 0 0 0 0 0 0 0 0 0 0 0 88
2021/2022676 34 56 120 35 36 7 5 44 37 7 33 262
2022/20231.879 136 112 74 173 163 215 2 116 792 5 64 27
2023/2024528 159 29 19 69 33 136 9 13 2 15 12 32
2024/20251.826 47 27 180 35 292 148 223 176 383 61 155 99
2025/20263.533 137 342 267 294 302 268 713 185 313 379 324 9
Totale 11.167